Roche's giredestrant 加上 Everolimus 慢化了44%的前期乳腺癌患者的晚期病情, Roche's giredestrant plus everolimus slowed advanced breast cancer progression by 44% in patients resistant to prior treatments, with strong results in those with ESR1 mutations.

Roche报告说,EVERA试验的第三阶段取得了积极结果,表明授精加永生素大大改善了在CDK4/6抑制剂和内分泌疗法方面已取得进展的ER-HER2-阴性高乳癌患者的无进展存活率。 Roche reported positive phase III results from the evERA trial, showing that giredestrant plus everolimus significantly improved progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer who had progressed on CDK4/6 inhibitors and endocrine therapy. 综合起来,总体疾病增加或死亡的风险降低了44%,中位PFS为8.77个月,而标准疗法为5.49个月。 The combination reduced the risk of disease progression or death by 44% overall, with a median PFS of 8.77 months versus 5.49 months for standard therapy. 对患有ESR1突变的患者的惠益更大,显示风险降低了62%。 Benefits were stronger in patients with ESR1 mutations, showing a 62% risk reduction. 结果在统计上意义重大,具有可管理的副作用,没有新的安全问题。 The results were statistically significant, with manageable side effects and no new safety issues. Roche计划向卫生当局提交数据,以备批准。 Roche plans to submit data to health authorities for potential approval.